From late February to late March 2026, China's interventional medical industry achieved breakthroughs across multiple fronts. Technological innovation, domestic products going global, and policy regulation advanced in tandem, accelerating the industry’s upgrade toward sophistication, localization, and intelligentization.

The domestic interventional medical industry has witnessed a series of major milestones, with technological innovation, overseas expansion of domestic brands, and policy oversight working in synergy to speed up its transformation into a high-end, localized, and intelligent sector. Recently, a number of China’s original technologies have taken the global lead. The team at Fuwai Hospital unveiled the world’s first solid implant-free cardiac occlusion technology, opening a new avenue for the treatment of atrial fibrillation. Multiple high-end interventional devices have been approved for market launch, addressing clinical challenges posed by complex coronary and macrovascular diseases. Academician Teng Gaojun’s team released a "Chinese Solution" for the combined interventional treatment of liver cancer. New technologies such as AI interventional robots and Yttrium-90 microspheres have been put into clinical application, significantly improving the accuracy and efficacy of diagnosis and treatment.

Chinese-made devices are accelerating their pace of internationalization. Several products from companies including MicroPort Endovascular and MicroPort NeuroTech have received authoritative international certifications, marking a leap from import substitution to global leadership. Clinically, cutting-edge minimally invasive procedures such as the implantation of extravascular defibrillators under local anesthesia have been adopted, providing safer and less invasive treatment. On the policy front, the centralized procurement of neurointerventional consumables has been fully implemented, effectively easing the financial burden on patients and encouraging the industry to focus on high-end innovation. With the widespread adoption of AI, intelligent navigation and other technologies, interventional diagnosis and treatment is entering a new era of precision and intelligence.

Efforts to standardize the industry have also moved forward steadily with the full implementation of centralized procurement for interventional medical consumables. On the one hand, this has effectively optimized the allocation of national medical resources, substantially reduced patients’ medical expenses, and continuously delivered benefits to public well-being. On the other hand, it has driven industry restructuring, prompting local enterprises to abandon homogeneous competition and concentrate on core technology research and development as well as product quality improvement, paving the way for the industry’s refined, high-quality and sound development.

In response to the rapid development of the interventional medical industry, the company will keep a close eye on cutting-edge trends, continue to deepen technological accumulation, strictly control product quality, and continuously strengthen its core competitiveness. With a pragmatic and committed approach, it will fully support the independent innovation and high-quality development of China’s interventional medical industry.